Biological cancer therapies: an approach towards accessibility

DISCUSSION: However, the costs for both the patient and the public health systems are still high, and the cost-effectiveness assessment must be optimized so that cost-effectiveness and access to time for patients can be compatible. And the challenge of developing new mAbs aimed at new targets, improving the safety profile, avoiding, or reducing adverse immune reactions and achieving lower production costs through improvements in biotechnology, is left open.PMID:36753623 | DOI:10.15446/rsap.V21n4.73686
Source: Revista de Salud Publica - Category: International Medicine & Public Health Authors: Source Type: research